Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Ticker SymbolELUT
Company nameElutia Inc
IPO dateOct 08, 2020
CEODr. C. Randal (Randal) Mills, Ph.D.
Number of employees51
Security typeOrdinary Share
Fiscal year-endOct 08
Address12510 Prosperity Drive
CitySILVER SPRING
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code20904
Phone12402471143
Websitehttps://elutia.com/
Ticker SymbolELUT
IPO dateOct 08, 2020
CEODr. C. Randal (Randal) Mills, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data